Recent clinical trials have shown that blocking immune checkpoint molecules can boost antitumour immune responses. In this Review, the authors consider whether targeting these pathways could also be used to combat a range of infectious diseases, such as malaria, tuberculosis and chronic viral infections.
- Michelle N. Wykes
- Sharon R. Lewin